RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:448267

Regressive spondylometaphyseal dysplasia

high confidenceDisorder

Publications

17

31.9th percentile

Trials

0

Interventional, condition-specific

Researchers

33

Distinct authors in sample

Gene link

LBR

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare, primary bone characterized by mild short stature, rhizomelic shortening of the arms and legs, bowing of long bones with widened and irregular metaphyses, thoracolumbar kyphosis, and metacarpal shortening. A marked improvement of the radiologic skeletal features is typical. Pelger-Huet anomaly (i.e. dumbbell shape bilobed nuclei of neutrophils) is a characteristic hematological feature of this disease.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

Pelger-Huet anomaly with mild skeletal anomalies · regressive spondylometaphyseal dysplasia

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Strong — LBR

  2. LiteraturePresent

    17 matched papers (14 in last 10 years) Source

  3. Phenotype characterisedPresent

    45 HPO annotations (e.g. Brachydactyly; Thoracic hypoplasia; Metaphyseal dysplasia) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (LBR).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

45

Associated phenotypes · MONDO:0018663

  • Brachydactyly
  • Thoracic hypoplasia
  • Metaphyseal dysplasia
  • Short femoral neck
  • Wide intermamillary distance

Showing 5 of 45 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

17

17 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

17 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

14 in the last 10 years · high confidence · 31.9th percentile (publications denominator)

Phrase hits: 6 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

33

Distinct author names in 6 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Altunoglu U1 paper · 2022

    Department of Medical Genetics, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.

    Papers in Europe PMC
  2. 02
    Berg JS1 paper · 2018

    Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

    Papers in Europe PMC
  3. 03
    Borah S1 paper · 2022

    National Institute of Immunohaematology, Mumbai, Maharashtra, India.

    Papers in Europe PMC
  4. 04
    Bosco M1 paper · 2019

    Pathological Anatomy and Histology Unit, San Lazzaro Hospital, Alba, Italy.

    Papers in Europe PMC
  5. 05
    Brown E1 paper · 2020

    Victorian Clinical Genetics Services, Royal Women's Hospital, Melbourne, VIC, Australia.

    Papers in Europe PMC
  6. 06
    Brusco A1 paper · 2019

    Department of Medical Sciences, University of Torino, Torino, Italy.

    Papers in Europe PMC
  7. 07
    Brussino A1 paper · 2019

    Department of Medical Sciences, University of Torino, Torino, Italy.

    Papers in Europe PMC
  8. 08
    Dhanasekaran K1 paper · 2022

    Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, Haryana, India.

    Papers in Europe PMC
  9. 09
    Dirimtekin E1 paper · 2025

    Department of Medical Genetics, School of Medicine, Marmara University, Istanbul, Turkey.

    Papers in Europe PMC
  10. 10
    Geckinli BB1 paper · 2025

    Department of Medical Genetics, School of Medicine, Marmara University, Istanbul, Turkey.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

high confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

Broader category spondylometaphyseal dysplasia also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Broader category: spondylometaphyseal dysplasia

0

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Parent-category matching found a broader label but no interventional trials under it. How we count trials.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Regressive spondylometaphyseal dysplasia — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Regressive spondylometaphyseal dysplasia" OR "Pelger-Huet anomaly with mild skeletal anomalies") OR ("LBR syndrome" OR "LBR-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Regressive spondylometaphyseal dysplasia" OR "Pelger-Huet anomaly with mild skeletal anomalies"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"spondylometaphyseal dysplasia"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T16:36:56.437Z